Peptide–nanoparticle conjugates: a next generation of diagnostic and therapeutic platforms?

Jeong, Woo Jin; Bu, Jong‐Uk; Kubiatowicz, Luke J.; Chen, Stephanie S; Kim, Young Soo; Hong, Seungpyo

doi:10.1186/s40580-018-0170-1

Cited by 174 publications

(122 citation statements)

References 131 publications

(146 reference statements)

Supporting

Mentioning

121

Contrasting

Unclassified

Order By: Relevance

“…Peptides different from antibodies do not destroy specificity or affinity and are small enough to weaken the vascular barrier to the lesion sites conveniently. The combination of peptides and nanoparticles overcomes the delivery barriers of many traditional drugs and provides a powerful strategy for the study of nanomedicines [26]. The previous study had demonstrated that the peptide VHPKQHR has high affinity with injured endothelial cells that are characteristic of atherosclerosis [27].…”

Section: Discussionmentioning

confidence: 99%

VHPKQHR peptide modified magnetic mesoporous nanoparticles for MRI detection of atherosclerosis lesions

Zhang

Zhou

et al. 2019

Artificial Cells, Nanomedicine, and Biotechnology

View full text Add to dashboard Cite

Mortality attributable to atherosclerosis can be reduced significantly with timely diagnosis and treatment. It is meaningful to find a proper way to diagnose and prevent the progression of atherosclerosis. Vascular cell adhesion molecule-1 (VCAM-1) expressed by endothelial cells is a prominent marker of atherosclerotic plaques. There are a number of researches on VCAM-1 based probes for targeted imaging, but rarely on a system with both targeting and drug delivery. Here, we report a novel magnetic mesoporous silicon nanoparticle that is capable of drug delivery and targeting at atherosclerosis plaque. The nanoparticles were constructed using incorporated FITC (fluorescein isothiocyanate) and VHPKQHR peptide into Fe 3 O 4 @SiO 2 (FITC-VHP-Fe 3 O 4 @SiO 2). The FITC-VHP-Fe 3 O 4 @SiO 2 nanoparticles showed great morphological characteristics, superior targeting ability, low toxicity and good biocompatibility in vitro and in vivo. The in vivo experiments showed that FITC-VHP-Fe 3 O 4 @SiO 2 is a superior contrast agent of magnetic resonance imaging (MRI) for diagnosis of atherosclerosis plaques.

show abstract

Section: Discussionmentioning

confidence: 99%

VHPKQHR peptide modified magnetic mesoporous nanoparticles for MRI detection of atherosclerosis lesions

Zhang

Zhou

et al. 2019

Artificial Cells, Nanomedicine, and Biotechnology

View full text Add to dashboard Cite

show abstract

“…They are classified according to their architecture into nanospheres, nanocapsules, conjugated polymers, and polyelectrolyte complexes [ 31 ]. Nanoparticles can be used to transport proteins and peptides, whose conjugation generates a synergistic effect that improves the limitations of each one of the materials and achieves uses, such as inhibition of the interactions of pathogenic proteins and high sensitivity in molecular imaging [ 32 , 33 , 34 ].…”

Section: Efforts To Overcome Peptide Limitationsmentioning

confidence: 99%

Peptides with Dual Antimicrobial–Anticancer Activity: Strategies to Overcome Peptide Limitations and Rational Design of Anticancer Peptides

2020

View full text Add to dashboard Cite

Peptides are naturally produced by all organisms and exhibit a wide range of physiological, immunomodulatory, and wound healing functions. Furthermore, they can provide with protection against microorganisms and tumor cells. Their multifaceted performance, high selectivity, and reduced toxicity have positioned them as effective therapeutic agents, representing a positive economic impact for pharmaceutical companies. Currently, efforts have been made to invest in the development of new peptides with antimicrobial and anticancer properties, but the poor stability of these molecules in physiological environments has triggered a bottleneck. Therefore, some tools, such as nanotechnology and in silico approaches can be applied as alternatives to try to overcome these obstacles. In silico studies provide a priori knowledge that can lead to the development of new anticancer peptides with enhanced biological activity and improved stability. This review focuses on the current status of research in peptides with dual antimicrobial–anticancer activity, including advances in computational biology using in silico analyses as a powerful tool for the study and rational design of these types of peptides.

show abstract

“…Several attempts have already been made to measure the transcytosis or penetration of diverse therapeutic agents through the BBB. In particular, surface-functionalized nanoparticles accompanied by encapsulation or surface-modification of drugs are an emerging technology for penetrating the BBB [103][104][105]. Chai et al developed red blood cell membrane-coated nanoparticles with a CDX peptide, which is derived from candoxin and shows a high-binding affinity with nicotinic acetylcholine receptors on the surface of the endothelial cell [106].…”

Section: Future Perspective and Conclusionmentioning

confidence: 99%

In Vitro Blood–Brain Barrier-Integrated Neurological Disorder Models Using a Microfluidic Device

2019

View full text Add to dashboard Cite

The blood–brain barrier (BBB) plays critical role in the human physiological system such as protection of the central nervous system (CNS) from external materials in the blood vessel, including toxicants and drugs for several neurological disorders, a critical type of human disease. Therefore, suitable in vitro BBB models with fluidic flow to mimic the shear stress and supply of nutrients have been developed. Neurological disorder has also been investigated for developing realistic models that allow advance fundamental and translational research and effective therapeutic strategy design. Here, we discuss introduction of the blood–brain barrier in neurological disorder models by leveraging a recently developed microfluidic system and human organ-on-a-chip system. Such models could provide an effective drug screening platform and facilitate personalized therapy of several neurological diseases.

show abstract

Peptide–nanoparticle conjugates: a next generation of diagnostic and therapeutic platforms?

Cited by 174 publications

References 131 publications

VHPKQHR peptide modified magnetic mesoporous nanoparticles for MRI detection of atherosclerosis lesions

VHPKQHR peptide modified magnetic mesoporous nanoparticles for MRI detection of atherosclerosis lesions

Peptides with Dual Antimicrobial–Anticancer Activity: Strategies to Overcome Peptide Limitations and Rational Design of Anticancer Peptides

In Vitro Blood–Brain Barrier-Integrated Neurological Disorder Models Using a Microfluidic Device

Contact Info

Product

Resources

About